0000921895-24-000773.txt : 20240403
0000921895-24-000773.hdr.sgml : 20240403
20240403091334
ACCESSION NUMBER: 0000921895-24-000773
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240325
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lazar David E.
CENTRAL INDEX KEY: 0001932843
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37367
FILM NUMBER: 24817045
MAIL ADDRESS:
STREET 1: 5305 VIDA RESIDENCE
STREET 2: MARSA
CITY: DUBAI
STATE: C0
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OPGEN INC
CENTRAL INDEX KEY: 0001293818
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 061614015
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9717 KEY WEST AVENUE
STREET 2: SUITE 100
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-869-9683
MAIL ADDRESS:
STREET 1: 9717 KEY WEST AVENUE
STREET 2: SUITE 100
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
3
1
form312227017laz_04022024.xml
OWNERSHIP DOCUMENT
X0206
3
2024-03-25
0
0001293818
OPGEN INC
OPGN
0001932843
Lazar David E.
VILLA 1, 14-43RD STREET
JUMEIRAH 2
DUBAI
C0
00000
UNITED ARAB EMIRATES
1
1
1
0
Chief Executive Officer
Common Stock
0
D
Series E Convertible Preferred Stock
2024-03-25
Common Stock
4800000
D
No shares of Common Stock are beneficially owned.
On March 25, 2024, David E. Lazar (the "Reporting Person") and OpGen, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire an aggregate of 3,000,000 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a price of $1.00 per share. Each share of Series E Preferred Stock is convertible into 24 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on March 25, 2024, whereby the Reporting Person acquired 200,000 shares of Series E Preferred Stock for a total purchase price of $200,000. The Reporting Person will acquire additional shares of Series E Preferred Stock at subsequent closings.
The Series E Preferred Stock is perpetual and therefore has no expiration date.
The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
/s/ David E. Lazar
2024-04-03